Endothelin receptor antagonists: A place in the management of essential hypertension?

Nephrology Dialysis Transplantation

Volumn 27, Issue 3, 2012, Pages 865-868

  Burnier, Michel ^a   Forni, Valentina ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Blood pressure; Endothelin receptors; Proteinuria fluid retention; Resistant hypertension

Indexed keywords

ATRASENTAN; AVOSENTAN; BOSENTAN; DARUSENTAN; ENALAPRIL; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; GUANFACINE; NIFEDIPINE; PLACEBO; SITAXSENTAN;

CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FLUID RETENTION; HEADACHE; HEART VENTRICLE OVERLOAD; HEMATOCRIT; HOT FLUSH; HUMAN; INCIDENCE; LEG EDEMA; MALIGNANT HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SODIUM RETENTION; STROKE;

ANTIHYPERTENSIVE AGENTS; DISEASE MANAGEMENT; HUMANS; HYPERTENSION; RECEPTORS, ENDOTHELIN;

EID: 84861122379     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr704     Document Type: Review

References (35)

1. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994; 46: 325-415
2. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86: 485-498
3. Abraham D, Dashwood M. Endothelin-role in vascular disease. Rheumatology 2008; 47 (Suppl 5): v23-v24
4. Kalra PR, Moon JC, Coats AJ. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 2002; 85: 195-197
5. Dhaun N, Goddard J, Webb DJ. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006; 17: 943-955
6. Battistini B, Berthiaume N, Kelland NF et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel ''-sentan'' class of drug. Exp Biol Med (Maywood) 2006; 231: 653-695
7. Hocher B, Thone-Reineke C, Bauer C et al. The paracrine endothelin system: pathophysiology and implications in clinical medicine. Eur J Clin Chem Clin Biochem 1997; 35: 175-189
8. Yokokawa K, Tahara H, KohnoMet al. Hypertension associated with endothelin-secreting malignant hemangio-endothelioma. Ann Intern Med 1991; 114: 213-215
9. Cardillo C, Kilcoyne CM, Waclawiw M et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999; 33: 753-758
10. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 2000; 36: 62-67
11. Dussaule JC, Boffa JJ, Tharaux PL et al. Endothelin, renal diseases, and hypertension. Adv Nephrol Necker Hosp 2000; 30: 281-303
12. Nakamura T, Ebihara I, Fukui M et al. Effect of a specific endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors in diabetic glomeruli. Diabetes 1995; 44: 895-899
13. Haynes WG, Ferro CJ, O'Kane KP et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-1870
14. Strachan FE, Spratt JC, Wilkinson IB et al. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999; 33: 581-585
15. Krum H, Viskoper RJ, Lacourciere Y et al. The effect of an endothelin- receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338: 784-790
16. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15: 583-589
17. Raichlin E, Prasad A, Mathew V et al. Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis. Hypertension 2008; 52: 522-528
18. Black HR, Bakris GL, Weber MA et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens 2007; 9: 760-769
19. Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 374: 1423-1431
20. Bakris GL, Lindholm LH, Black HR et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension 2010; 56: 824-830
21. Rabelink TJ, Kaasjager KA, Boer P et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int 1994; 46: 376-381
22. Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29: 2-26
23. Goddard J, Johnston NR, Hand MF et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193
24. Dhaun N, Ferro CJ, Davenport AP et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3228-3234
25. Orisio S, Benigni A, Bruzzi I et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43: 354-358
26. Hocher B, Schwarz A, Reinbacher D et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001; 87: 161-169
27. Dhaun N, Macintyre IM, Melville V et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119
28. Wenzel RR, Littke T, Kuranoff S et al. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664
29. Sasser JM, Sullivan JC, Hobbs JL et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-154
30. Amann K, Simonaviciene A, Medwedewa T et al. Blood pressureindependent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a lowrenin model of renal damage. J Am Soc Nephrol 2001; 12: 2572-2584
31. Goddard J, Eckhart C, Johnston NR et al. Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism. J Am Soc Nephrol 2004; 15: 2601-2610
32. Dhaun N, MacIntyre IM, Kerr D et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779
33. Mann JF, Green D, Jamerson K et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535
34. Smolander J, Vogt B, Maillard M et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 2009; 85: 628-634
35. Maillard M, Wang Q, Baltatu O et al. Do endothelin receptor antagonists induce edema through an extravasation of fluids? Evidence from an experiment in bi-nephrectomized rats. J Hypertens 2008; 26 (Suppl 1): 371. Abstract